Video Experimental Relacionado
Updated: May 13, 2026
10:47
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
Los conjugados de gemcitabina-cumarina-biotina: un prodrogo anticancerígeno teránostico específico del objetivo
Sukhendu Maiti1, Nayoung Park, Ji Hye Han
1Department of Chemistry, Korea University, Seoul, 136-701, Korea.
Journal of the American Chemical Society
|March 7, 2013
Resumen
Este estudio introduce un nuevo gemcitabina-cumarina-biotina conjugado para el cáncer theranostics. Este conjugado libera el fármaco activo gemcitabina (GMC) y mejora la fluorescencia en respuesta a los tiolos de las células tumorales.
Área de la Ciencia:
- Bioconjugado Química Bioconjugado
- Imágenes moleculares de imágenes.
- Sistemas de suministro de drogas Sistemas de suministro de drogas.
Sus antecedentes:
- Las células cancerosas exhiben niveles elevados de tiolos libres.
- La administración de fármacos dirigida y el monitoreo en tiempo real son cruciales para una terapia eficaz contra el cáncer.
- La gemcitabina (GMC) es un medicamento de quimioterapia ampliamente utilizado.
Objetivo del estudio:
- Diseñar y sintetizar un conjugado multifuncional para la terapia y el diagnóstico dirigidos del cáncer.
- Para evaluar la liberación del fármaco, la respuesta de fluorescencia y la absorción celular del conjugado.
- Para investigar la localización intracelular y el mecanismo de acción.
Principales métodos:
- Síntesis y caracterización espectroscópica del conjugado gemcitabina-cumarina-biotina.
- Evaluación biológica in vitro que incluye estudios de captación celular (microscopía confocal) y ensayos de colocalización.
- Evaluación de la liberación de fármacos inducida por el tiol y el aumento de la fluorescencia.
Principales resultados:
- El conjugado (5) demostró una absorción preferente en las células cancerosas A549 en comparación con las células WI38.
- La escisión del enlace disulfuro inducida por el tiol condujo a la liberación de gemcitabina (GMC) y al aumento de la fluorescencia.
- Los estudios de colocalización indicaron absorción y escisión lisosómica, potencialmente a través de endocitosis mediada por el receptor.
Conclusiones:
- El conjugado gemcitabina-cumarina-biotina desarrollado funciona como un agente teránostico para el cáncer.
- Permite la administración simultánea de fármacos terapéuticos y el monitoreo de la absorción de fármacos a nivel subcelular.
- Este sistema ofrece un enfoque prometedor para la imagen y el tratamiento avanzado del cáncer.
Videos de Conceptos Relacionados
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...